TriSalus Life Sciences Inc (TLSI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...

GuruFocus News

Fri, May 16, 2025, 12:01 PM 3 min read

Release Date: May 15, 2025

For the implicit transcript of the net call, delight notation to the full net telephone transcript.

• TriSalus Life Sciences Inc (NASDAQ:TLSI) reported a 42% summation successful nett income for Q1 2025 compared to Q1 2024, demonstrating beardown gross growth.

• The institution achieved important milestones, including the completion of signifier 1 trials for Nelatolamo, positioning it for imaginable pharmaceutical partnerships.

• TLSI expanded its commercialized footprint by expanding the fig of unsocial ordering accounts by 39% compared to Q1 2024, adding 32 caller accounts.

• The Centers for Medicare and Medicaid Services issued a caller reimbursement codification for TriNav, doubling its reimbursable usage and supporting broader adoption.

• TLSI successfully raised astir $22 cardinal successful gross proceeds done a backstage placement, strengthening its fiscal presumption for aboriginal investments.

• Despite gross growth, TLSI reported operating losses of $7.3 cardinal for Q1 2025, though this was an betterment from the erstwhile year.

• The company's gross borderline decreased somewhat to 84% successful Q1 2025 from 85% successful Q1 2024 owed to decreased mill volumes during cleanable country expansion.

• TLSI does not expect being EBITDA affirmative oregon currency travel affirmative successful 2025, arsenic it continues to put successful strategical areas of the business.

• The institution faces challenges successful scaling its income unit and ensuring caller hires are efficaciously integrated to thrust meaningful volume.

• There is uncertainty regarding the last information and outcomes from the Nelatolamo trials, which could interaction imaginable partnerships and aboriginal revenue.

• Warning! GuruFocus has detected 5 Warning Signs with TLSI.

Q: What should we beryllium looking for successful the ero 03 readout, and what would beryllium an charismatic result for imaginable partners? A: This was a signifier 1 dose-ranging proceedings utilizing a caller PEDD instrumentality for pancreatic tumors. The instrumentality performed good with minimal broadside effects. The survey collected correlative data, including insubstantial samples and cytokine levels, with secondary endpoints of wide survival. About 50% of the 12 patients are inactive alive, which is promising. Potential partners are funny successful however the cause stimulates the tumor situation and its information profile.

Q: Are you seeing involvement successful Nelatolamo connected its ain oregon successful conjunction with TriNav, and however mightiness partnerships beryllium structured? A: Nelatolamo is optimized done our PEDD technology, which allows for nonstop tumor delivery. The extremity is to spouse with pharmaceutical companies, handling the procedural facet and perchance participating connected the cause side. PEDD is seen arsenic a level for delivering assorted drugs, enhancing tumor attraction portion maintaining systemic delivery.